Precision in Practice

Using minimally invasive laserablation

Aiming for the precise

The challenges in healthcare are many. At CLS we are committed to developing better therapies for use in cancer care and neurosurgery. We do this by providing tools for precise tissue ablation using heat generated by laser light. Our close collaboration with healthcare professionals ensures our products meet their requirements and seamlessly fits into hospital workflows. This enables more patients to be treated based on their specific diagnosis and needs. Carefully precise.

Focal therapy in localized prostate cancer

Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally without damaging healthy tissue. The procedure is minimally invasive and thus gentle on the patient, who typically can return quickly to normal life. 

brain-therapy


Careful therapy of brain lesions

A tumor or epileptogenic foci in the brain means major challenges – for the patient and for healthcare. When using laser ablation in neurosurgery the lesion is directly targeted and treated with high precision. The treatment spares healthy tissue and causes less side effects than surgery and chemotherapy.

Immune stimulating laser ablation – using new hot technology

The thermal effects on cells depend mainly on two factors – temperature and time. Research has shown that moderate heating of cancerous tumor cells during a long time will not only kill the targeted tumor itself, but also activate the immune system to attack cancer cells throughout the body.

Integrated therapy systems for high precision laser ablation

Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed CLS TRANBERG® Thermal Therapy Systems – seamlessly integrated systems for laser ablation, with several options for real time monitoring and control of the treatment.

Annual General Meeting 2022

Pipeline

Research is just the beginning - and that is where it all began for CLS. We are now running various clinical studies to develop new therapies in the fight against serious diseases such as cancer.

Investor relations

CLS is listed on Nasdaq First North Growth Market. Our aim is to provide relevant and transparent information for analysts, investors and media with the latest financial reports, events, news and the development of CLS’s share.

News and insights

28 November, 2022

Clinical data from a Phase II trial using CLS TRANBERG products presented during RSNA 2022 Annual Meeting

The RSNA (Radiological Society of North America) annual meeting is ongoing in Chicago, the US. Yesterday, interim data from the ongoing study in Toronto using CLS´s TRANBERG products, was presented by the principal investigator MD Sangeet Ghai.   

Read more
24 November, 2022

Our CTO Cristina Pantaleone awarded Technician of the Year by the Chamber of Commerce

We are happy to announce that our Chief Technology Officer Cristina Pantaleone today has been awarded Technician of the Year by the Chamber of Commerce and Industry of Southern Sweden.

Read more
8 November, 2022

Scientific presentations related to the use of CLS TRANBERG® products at the 13th iMRI Symposium in Leipzig

We want to highlight a couple of scientific presentations held during the 13th Interventional MRI Symposium 2022 in Leipzig, October 14-15, 2022. This event provides an ideal platform for researchers, clinicians, and healthcare professionals alike to present their latest results within interventional MRI.

Read more

Sign up for our
newsletter

Make sure you get all the exciting information about CLS’ progress on an ongoing basis.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!


Please choose your country or region

Global
US